Shire finally gets Baxalta to the deal-talks table

Shire CEO Flemming Ornskov

Shire ($SHPG) is reportedly one step closer to achieving its dream of nabbing Baxalta ($BXLT) to become a global rare-disease leader. The two companies are in takeover talks, Bloomberg reported Friday, with the Illinois pharma looking for a sweetened bid with a cash component. The way Shire sees it, a combined company could generate $20 billion in sales by 2020, with as many as 30 new drugs rolling out over the next 5 years, CEO Flemming Ornskov has said. More from FiercePharma

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.